Beyond Cas9: The New Enzymes
CRISPR-Cas9 was revolutionary but had limitations. Off-target edits, delivery challenges, and immune responses limited its clinical use. The next generation addresses these problems directly.
Cas12 and Cas13: Precision Tools
Cas12 creates staggered cuts instead of blunt cuts, making it easier to insert new DNA sequences precisely. Cas13 targets RNA instead of DNA, enabling transient edits that do not permanently alter the genome.
Base Editing
Developed by David Lius lab at the Broad Institute, base editors can change a single DNA base pair without cutting the DNA strand at all. Since about 60% of disease-causing mutations are single-base changes, this technique is transformative.
Prime Editing: Search and Replace
Prime editing combines a Cas9 nickase with a reverse transcriptase, allowing researchers to search and replace DNA sequences without double-strand breaks. It can correct up to 89% of known disease-causing mutations.
Clinical Reality (2026)
The first CRISPR therapy, Casgevy, was approved in 2023 for sickle cell disease. The next generation aims for in vivo editing: injecting therapy directly into the patient.
The first in vivo CRISPR therapy entered trials in 2024. If successful, it would transform gene therapy from a hospital procedure into an injection.